ClinConnect ClinConnect Logo
Search / Trial NCT06182319

Optimizing Treatment of Adhesive Small Bowel Obstruction

Launched by UNIVERSITY OF CALIFORNIA, LOS ANGELES · Dec 22, 2023

Trial Information

Current as of July 01, 2025

Recruiting

Keywords

Nasogastric Tube (Ngt) Water Soluble Contrast (Wsc) Adhesion Related Sbo (A Sbo) Small Bowel Obstruction (Sbo)

ClinConnect Summary

This clinical trial is studying the best ways to treat adhesive small bowel obstruction (aSBO), a condition where the intestines become blocked due to scar tissue from previous surgeries or injuries. The researchers want to find out if using a nasogastric tube (NGT) to relieve stomach pressure or using a special liquid called water-soluble contrast (WSC) is helpful for patients with this condition. They aim to see who benefits from these treatments, how to tell when the obstruction has cleared, and the best way to safely start feeding patients again after treatment.

To participate in this study, individuals need to be at least 18 years old and have signs of aSBO, such as nausea, abdominal pain, or a swollen belly confirmed by a CT scan. However, pregnant or breastfeeding women, those with certain serious health conditions, and individuals with other types of bowel obstructions are not eligible. The trial will include about 40 participants who will be monitored for up to 30 days, allowing researchers to gather important information about the treatment's effectiveness and safety.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • 1. Male or female ≥18 years of age.
  • 2. Documentation of aSBO as evidenced by one or more clinical features meeting the following criteria: Nausea, emesis, abdominal pain, distended abdomen CT evidence of aSBO
  • Exclusion Criteria:
  • 1. Pregnant, breastfeeding, or unwilling to practice birth control during participation in the study.
  • 2. Presence of a condition or abnormality that in the opinion of the investigator would compromise the safety of the patient or the quality of the data.
  • 3. Unstable angina or recent myocardial infarction (MI)/stroke within 6 months
  • 4. Nonadhesive SBO
  • 1. Paralytic Ileus
  • 2. Incarcerated hernia
  • 3. Fecal impaction
  • 4. Intra-abdominal malignancy Early aSBO within 4 weeks of a prior abdominal operation

About University Of California, Los Angeles

The University of California, Los Angeles (UCLA) is a prestigious academic institution renowned for its commitment to research and innovation in the biomedical field. As a clinical trial sponsor, UCLA leverages its cutting-edge facilities, expert faculty, and collaborative environment to advance medical knowledge and improve patient care. The university is dedicated to conducting rigorous clinical research that adheres to the highest ethical standards, aiming to translate scientific discoveries into effective therapies and interventions. Through its diverse array of clinical trials, UCLA seeks to address critical health challenges while fostering the development of future healthcare leaders.

Locations

Los Angeles, California, United States

Patients applied

0 patients applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported